Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia
Fig 5
Antibody responses to SARS-CoV-2 vaccine peak at Day 28 in those with low pre-existing immunity to Ad5.
Geometric mean titres in response to serum antibodies A) S protein, B) RBD, C) neutralising antibodies against SARS-CoV-2 (NAbs) and D) Ad5 neutralising antibodies were examined on Day 0, Day 14, Day 28 and Month 6 after vaccination. Participants from the FAS for immunogenicity analysis population that received the Ad5-nCoV vaccine (n = 371) were divided into seven subgroups (from 1:5 to 1:320) based on their pre-existing anti-Ad5 antibody levels. Ad5, adenovirus type-5; RBD, receptor binding domain; S, spike; SARS-CoV 2, severe acute respiratory syndrome coronavirus 2.